The Wall Street Journal
@WSJ
Sign up for our newsletters and alerts: | Got a tip? | For WSJ customer support:
Joined April 2007
1.1K Following 22.3M Followers
The company said the late-stage study for its pelacarsen drug missed its primary objective of reducing the risk of cardiovascular events like death, heart attack and stroke compared with placebo.
Show more
